CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
| Authors | |
|---|---|
| Year of publication | 2011 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate. |
| Related projects: |